Redmile Group LLC lowered its position in shares of Replimune Group, Inc. (NASDAQ:REPL – Free Report) by 3.5% during the first quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 3,729,983 shares of the company’s stock after selling 135,275 shares during the period. Redmile Group LLC owned about 6.08% of Replimune Group worth $30,474,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds have also bought and sold shares of the company. Price T Rowe Associates Inc. MD grew its holdings in shares of Replimune Group by 12.0% during the first quarter. Price T Rowe Associates Inc. MD now owns 6,548,930 shares of the company’s stock worth $53,505,000 after purchasing an additional 699,679 shares during the last quarter. Fcpm Iii Services B.V. bought a new stake in Replimune Group during the 4th quarter worth approximately $41,024,000. Vanguard Group Inc. increased its position in Replimune Group by 1.2% in the 1st quarter. Vanguard Group Inc. now owns 2,770,328 shares of the company’s stock valued at $22,634,000 after acquiring an additional 32,555 shares during the period. Goldman Sachs Group Inc. increased its position in Replimune Group by 300.3% in the 4th quarter. Goldman Sachs Group Inc. now owns 2,238,883 shares of the company’s stock valued at $18,874,000 after acquiring an additional 1,679,553 shares during the period. Finally, Rafferty Asset Management LLC raised its stake in shares of Replimune Group by 148.1% during the fourth quarter. Rafferty Asset Management LLC now owns 463,397 shares of the company’s stock valued at $3,906,000 after acquiring an additional 276,596 shares during the last quarter. Institutional investors and hedge funds own 92.53% of the company’s stock.
Wall Street Analysts Forecast Growth
Several analysts recently weighed in on the stock. HC Wainwright boosted their price objective on shares of Replimune Group from $12.00 to $17.00 and gave the stock a “buy” rating in a research note on Friday, June 7th. Barclays increased their price target on Replimune Group from $13.00 to $17.00 and gave the company an “overweight” rating in a research note on Friday, June 7th. Finally, Wedbush reaffirmed an “outperform” rating and issued a $16.00 price objective on shares of Replimune Group in a research note on Thursday, June 6th.
Replimune Group Trading Down 2.8 %
NASDAQ REPL traded down $0.29 during mid-day trading on Monday, reaching $10.06. 503,088 shares of the stock were exchanged, compared to its average volume of 1,250,605. The stock has a market cap of $617.83 million, a P/E ratio of -3.10 and a beta of 1.24. The company has a debt-to-equity ratio of 0.18, a current ratio of 10.72 and a quick ratio of 10.72. Replimune Group, Inc. has a one year low of $4.92 and a one year high of $21.63. The stock has a 50 day simple moving average of $8.18 and a 200-day simple moving average of $7.80.
Replimune Group (NASDAQ:REPL – Get Free Report) last posted its quarterly earnings data on Thursday, May 16th. The company reported ($0.82) earnings per share for the quarter, topping the consensus estimate of ($0.86) by $0.04. On average, analysts anticipate that Replimune Group, Inc. will post -3.31 EPS for the current year.
Insider Buying and Selling at Replimune Group
In related news, Chairman Philip Astley-Sparke sold 37,928 shares of the business’s stock in a transaction on Thursday, May 16th. The shares were sold at an average price of $6.47, for a total transaction of $245,394.16. Following the transaction, the chairman now owns 1,487,350 shares in the company, valued at approximately $9,623,154.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other Replimune Group news, Director Robert Coffin sold 11,464 shares of the stock in a transaction that occurred on Thursday, May 16th. The stock was sold at an average price of $6.47, for a total value of $74,172.08. Following the transaction, the director now owns 1,821,872 shares in the company, valued at $11,787,511.84. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Chairman Philip Astley-Sparke sold 37,928 shares of Replimune Group stock in a transaction dated Thursday, May 16th. The shares were sold at an average price of $6.47, for a total transaction of $245,394.16. Following the transaction, the chairman now owns 1,487,350 shares of the company’s stock, valued at $9,623,154.50. The disclosure for this sale can be found here. Over the last three months, insiders have sold 107,598 shares of company stock valued at $712,516. 20.60% of the stock is currently owned by company insiders.
Replimune Group Profile
Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.
See Also
- Five stocks we like better than Replimune Group
- Want to Profit on the Downtrend? Downtrends, Explained.
- Survey: Top 175 Fittest Retirement Locations in America
- Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?
- Kimberly-Clark Stock Dips and a Buying Opportunity Emerges
- Unveiling The Power Of VWAP: A Key Indicator For Traders
- Leading Gold Stock Shines With Q2 2024 Earnings Release
Want to see what other hedge funds are holding REPL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Replimune Group, Inc. (NASDAQ:REPL – Free Report).
Receive News & Ratings for Replimune Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Replimune Group and related companies with MarketBeat.com's FREE daily email newsletter.